Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment

Farshad Moradi, Heying Duan, Hong Song, Guido A. Davidzon, Benjamin I. Chung, Alan E. C. Thong, Andreas M. Loening, Pejman Ghanouni, Geoffrey Sonn and Andrei Iagaru
Journal of Nuclear Medicine December 2022, 63 (12) 1822-1828; DOI: https://doi.org/10.2967/jnumed.122.263897
Farshad Moradi
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heying Duan
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Song
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guido A. Davidzon
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin I. Chung
2Department of Urology, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan E. C. Thong
2Department of Urology, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas M. Loening
3Division of Body MRI, Department of Radiology, Stanford University, Stanford, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pejman Ghanouni
3Division of Body MRI, Department of Radiology, Stanford University, Stanford, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Sonn
2Department of Urology, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrei Iagaru
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 63 no. 12 1822-1828
DOI 
https://doi.org/10.2967/jnumed.122.263897
PubMed 
35512996

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 18, 2022
  • Revision received April 22, 2022
  • Published online December 1, 2022.

Article Versions

  • previous version (May 5, 2022 - 11:48).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Farshad Moradi1,
  2. Heying Duan1,
  3. Hong Song1,
  4. Guido A. Davidzon1,
  5. Benjamin I. Chung2,
  6. Alan E. C. Thong2,
  7. Andreas M. Loening3,
  8. Pejman Ghanouni3,
  9. Geoffrey Sonn2 and
  10. Andrei Iagaru1
  1. 1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  2. 2Department of Urology, Stanford University, Stanford, California; and
  3. 3Division of Body MRI, Department of Radiology, Stanford University, Stanford, California
  1. For correspondence or reprints, contact Farshad Moradi (fmoradi{at}stanford.edu).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 1 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters
    Ioana M. Marinescu, Manuel Rogg, Simon Spohn, Moritz von Büren, Marius Kamps, Cordula A. Jilg, Elena Fountzila, Kyriaki Papadopoulou, Lara Ceci, Alisa Bettermann, Juri Ruf, Matthias Benndorf, Sonja Adebahr, Daniel Zips, Anca L. Grosu, Christoph Schell, Constantinos Zamboglou
    Radiation Oncology 2022 17 1

Article usage

Article usage: May 2022 to February 2023

AbstractFullPdf
May 20222123080
Jun 2022470010
Jul 202232503
Aug 202218608
Sep 202220105
Oct 2022203010
Nov 2022121021
Dec 202216686585
Jan 2023137391105
Feb 2023653731
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (12)
Journal of Nuclear Medicine
Vol. 63, Issue 12
December 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment
Farshad Moradi, Heying Duan, Hong Song, Guido A. Davidzon, Benjamin I. Chung, Alan E. C. Thong, Andreas M. Loening, Pejman Ghanouni, Geoffrey Sonn, Andrei Iagaru
Journal of Nuclear Medicine Dec 2022, 63 (12) 1822-1828; DOI: 10.2967/jnumed.122.263897

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment
Farshad Moradi, Heying Duan, Hong Song, Guido A. Davidzon, Benjamin I. Chung, Alan E. C. Thong, Andreas M. Loening, Pejman Ghanouni, Geoffrey Sonn, Andrei Iagaru
Journal of Nuclear Medicine Dec 2022, 63 (12) 1822-1828; DOI: 10.2967/jnumed.122.263897
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer
  • PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study
  • 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy
Show more Clinical Investigation

Similar Articles

Keywords

  • Oncology: GU
  • PET
  • PET/MRI
  • Prostate Cancer
  • biochemical recurrence
  • prostate-specific membrane
  • antigen
  • prostatectomy
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire